Nueva publicación @LunaMinute@arlosdel acerca de cómo funcionan las #vacunas de mucosa basadas en inmunidad entrenada (TIbVs) en la prevención de infecciones respiratorias, entre ellas MV130, desarrollada por @Inmunotek
📄 https://t.co/SABRrf3YIb
#AMR#InmunidadEntrenada
1/3 📢 New research on MV130, a mucosal polybacterial vaccine developed by @inmunotek , shows potential in attenuating experimental ulcerative colitis. It reduces inflammation, protects the gut barrier, and promotes immune tolerance: https://t.co/UeMmoI3HwN
@SilviaSchzRamon@SEinmunologia Enhorabuena Silvia! Vas a poner muy arriba a la SEI y el listón muy alto para los siguientes. Que tengas mucha suerte con el reto! Un fuerte abrazo!!
Biomedicines | Free Full-Text | Long-Term Benefit of Perlingual Polybacterial Vaccines in Patients with Systemic Autoimmune Diseases and Active Immunosuppression https://t.co/hRtJayXP92
Terrific panel of speakers for the WISH-A meeting in Alicante. Really thankful to have been invited to give a talk. Thank you @inmunotek. Feeling strong from @IdipazScience !!
Voilà! Our new study is out in @FrontImmunol. Thank you for the nice collaboration. Now on to the next one! @ozlemthefrogge @mariacegove 🧫⬇️
https://t.co/S1Cr0QTW17
Vaccine curious? Hear Prof. Netea tells how he discovered that vaccines can affect the innate immune system (previously believed to be without a memory) in profound ways - and how that may affect the use of vaccines in the future. https://t.co/VcvmJyZ92N
https://t.co/2AmrGIWy8e
Nieto, et al., First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual #immunotherapy.
Read the article here👉 https://t.co/mjsICBPgPw
See more papers👉 https://t.co/oHigjNq0sS
#Allergy_journal
▷ Tengo algo importante que decirte: estoy ahora mismo en la mesa redonda que organiza @Cepyme_ bajo el título: Claves del Presente y Futuro de la Digitalización de la PYME Española?
¿Dónde? En el @cbamadrid con @carmeartigas y
@josezimmer
📣Calling early career researchers!
We invite researchers within 15 years of completing their Ph.D., M.D., or equivalent terminal degrees to submit to:
Rising Stars in in Allergen Immunotherapy Research: 2022
👉https://t.co/56Lpd6JzpR
#callforpapers#openaccess@JoseSubiza